Adial Pharmaceuticals- Warrants (31/07/2023) EBIT

The latest EBIT for ADILW is $-58M as of June 2026. That compares with $-8.3M in the prior-year period — down 594.7% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Adial Pharmaceuticals- Warrants (31/07/2023)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, ADILW's EBIT moved from $-8.3M to $-58M — a 594.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Adial Pharmaceuticals- Warrants (31/07/2023)'s operating scale or balance-sheet position.

Against Healthcare companies, ADILW currently prints $-58M for EBIT, while the sector average sits near $23B. That is roughly 100.3% below the sector mean. Large gaps often invite a closer look at Adial Pharmaceuticals- Warrants (31/07/2023)'s growth, margins, and balance sheet.

A EBIT figure of $-58M for ADILW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting ADILW's EBIT ($-58M), review year-over-year change from $-8.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.